These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 11278577)
1. Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism. Gangloff M; Ruff M; Eiler S; Duclaud S; Wurtz JM; Moras D J Biol Chem; 2001 May; 276(18):15059-65. PubMed ID: 11278577 [TBL] [Abstract][Full Text] [Related]
2. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Shiau AK; Barstad D; Loria PM; Cheng L; Kushner PJ; Agard DA; Greene GL Cell; 1998 Dec; 95(7):927-37. PubMed ID: 9875847 [TBL] [Abstract][Full Text] [Related]
3. Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity. Greschik H; Flaig R; Renaud JP; Moras D J Biol Chem; 2004 Aug; 279(32):33639-46. PubMed ID: 15161930 [TBL] [Abstract][Full Text] [Related]
4. Synergism between ERalpha transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 alpha-helical core and for a direct interaction between the N- and C-terminal domains. Métivier R; Penot G; Flouriot G; Pakdel F Mol Endocrinol; 2001 Nov; 15(11):1953-70. PubMed ID: 11682626 [TBL] [Abstract][Full Text] [Related]
5. X-ray crystal structures of the estrogen-related receptor-gamma ligand binding domain in three functional states reveal the molecular basis of small molecule regulation. Wang L; Zuercher WJ; Consler TG; Lambert MH; Miller AB; Orband-Miller LA; McKee DD; Willson TM; Nolte RT J Biol Chem; 2006 Dec; 281(49):37773-81. PubMed ID: 16990259 [TBL] [Abstract][Full Text] [Related]
6. Ligand-induced changes in estrogen receptor conformation as measured by site-directed spin labeling. Hurth KM; Nilges MJ; Carlson KE; Tamrazi A; Belford RL; Katzenellenbogen JA Biochemistry; 2004 Feb; 43(7):1891-907. PubMed ID: 14967030 [TBL] [Abstract][Full Text] [Related]
7. Conformational dynamics of the estrogen receptor alpha: molecular dynamics simulations of the influence of binding site structure on protein dynamics. Celik L; Lund JD; Schiøtt B Biochemistry; 2007 Feb; 46(7):1743-58. PubMed ID: 17249692 [TBL] [Abstract][Full Text] [Related]
8. Mutation of Leu-536 in human estrogen receptor-alpha alters the coupling between ligand binding, transcription activation, and receptor conformation. Zhao C; Koide A; Abrams J; Deighton-Collins S; Martinez A; Schwartz JA; Koide S; Skafar DF J Biol Chem; 2003 Jul; 278(29):27278-86. PubMed ID: 12736255 [TBL] [Abstract][Full Text] [Related]
9. Molecular basis of agonism and antagonism in the oestrogen receptor. Brzozowski AM; Pike AC; Dauter Z; Hubbard RE; Bonn T; Engström O; Ohman L; Greene GL; Gustafsson JA; Carlquist M Nature; 1997 Oct; 389(6652):753-8. PubMed ID: 9338790 [TBL] [Abstract][Full Text] [Related]
10. Evidence for ligand-independent transcriptional activation of the human estrogen-related receptor alpha (ERRalpha): crystal structure of ERRalpha ligand binding domain in complex with peroxisome proliferator-activated receptor coactivator-1alpha. Kallen J; Schlaeppi JM; Bitsch F; Filipuzzi I; Schilb A; Riou V; Graham A; Strauss A; Geiser M; Fournier B J Biol Chem; 2004 Nov; 279(47):49330-7. PubMed ID: 15337744 [TBL] [Abstract][Full Text] [Related]
13. Structural insights into the mode of action of a pure antiestrogen. Pike AC; Brzozowski AM; Walton J; Hubbard RE; Thorsell AG; Li YL; Gustafsson JA; Carlquist M Structure; 2001 Feb; 9(2):145-53. PubMed ID: 11250199 [TBL] [Abstract][Full Text] [Related]
14. Overexpression, purification, and crystal structure of native ER alpha LBD. Eiler S; Gangloff M; Duclaud S; Moras D; Ruff M Protein Expr Purif; 2001 Jul; 22(2):165-73. PubMed ID: 11437591 [TBL] [Abstract][Full Text] [Related]
15. Crystal structure of human estrogen-related receptor alpha in complex with a synthetic inverse agonist reveals its novel molecular mechanism. Kallen J; Lattmann R; Beerli R; Blechschmidt A; Blommers MJ; Geiser M; Ottl J; Schlaeppi JM; Strauss A; Fournier B J Biol Chem; 2007 Aug; 282(32):23231-9. PubMed ID: 17556356 [TBL] [Abstract][Full Text] [Related]
16. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. Pike AC; Brzozowski AM; Hubbard RE; Bonn T; Thorsell AG; Engström O; Ljunggren J; Gustafsson JA; Carlquist M EMBO J; 1999 Sep; 18(17):4608-18. PubMed ID: 10469641 [TBL] [Abstract][Full Text] [Related]
17. Charge clamps of lysines and hydrogen bonds play key roles in the mechanism to fix helix 12 in the agonist and antagonist positions of estrogen receptor α: intramolecular interactions studied by the ab initio fragment molecular orbital method. Watanabe C; Fukuzawa K; Tanaka S; Aida-Hyugaji S J Phys Chem B; 2014 May; 118(19):4993-5008. PubMed ID: 24725156 [TBL] [Abstract][Full Text] [Related]
18. Molecular modelling of the human estrogen receptor and ligand interactions based on site-directed mutagenesis and amino acid sequence homology. Lewis DF; Parker MG; King RJ J Steroid Biochem Mol Biol; 1995 Jan; 52(1):55-65. PubMed ID: 7857874 [TBL] [Abstract][Full Text] [Related]
19. Understanding the human estrogen receptor-alpha using targeted mutagenesis. Skafar DF; Koide S Mol Cell Endocrinol; 2006 Feb; 246(1-2):83-90. PubMed ID: 16442702 [TBL] [Abstract][Full Text] [Related]
20. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Shiau AK; Barstad D; Radek JT; Meyers MJ; Nettles KW; Katzenellenbogen BS; Katzenellenbogen JA; Agard DA; Greene GL Nat Struct Biol; 2002 May; 9(5):359-64. PubMed ID: 11953755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]